AI must increasingly meet budget constraints, according to co-founder and CEO of Gleamer Christian Allouche, who spoke with Mélisande Rouger during RSNA2023, the annual meeting of the Radiological Society of North America that took place November 26-29 in Chicago, U.S.
‘Queries from our customers are now that AI meets the budget constraints that they have,’ he said. ‘We raised 27M EUR last June to build a large catalogue of proprietary AI applications, to be able to bundle its price and meet these constraints while fostering AI adoption.’
Most companies now have one of two products in their portfolio and not so many did take this industrial way of delivering new AI applications in the market, he went on. ‘Our main focus is how to organize the company internally, so that we can launch a number of new applications with very high level of performance.’
At RSNA2023, Gleamer presented two of its newest products hat have FDA pending approvals: ChestView, which enhances the detection of urgent chest findings, and BoneMetrics, which automates MSK measurements. The company also showcased four new AI applications around mammography and CT for oncology that will be released in Europe next year.